Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $51.8 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 53.6% year-over-year to $51.8 million in Q1 2026; TTM through Mar 2026 was $51.8 million, a 53.6% increase from a year earlier, with the FY2025 full-year figure at $70.7 million, up 47.67% from the prior year.
• Total Current Liabilities declined to $51.8 million in Q1 2026 per VRDN's latest filing, from $70.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $70.7 million in Q4 2025 and bottomed at $14.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $33.3 million (2022), against an average of $36.1 million.
• Across the five-year window, Total Current Liabilities soared 144.57% in 2022 and slipped 20.13% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $33.3 million in 2022, then retreated by 20.13% to $26.6 million in 2023, then surged by 79.74% to $47.9 million in 2024, then jumped by 47.67% to $70.7 million in 2025, then slipped by 26.72% to $51.8 million in 2026.
• Per Business Quant, the three latest VRDN Total Current Liabilities figures stand at $51.8 million (Q1 2026), $70.7 million (Q4 2025), and $50.7 million (Q3 2025).